Loading page…

Report overview

The report presents FY2017-18 consolidated sales of US$ 604 million and consolidated total revenue of ₹4,057 crore. It highlights the company's antibiotic pipeline, including five breakthrough NCEs granted QIDP status and several progressing through Phase III studies. R&D investment including capex reached ₹443 crore, while CSR initiatives reported more than 74 million lives touched. The report also records 6,254 employees and a two-woman, 11-member board.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Publication date: 4 May 2018
Language
Pages
File size

Standards & Assurance

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services